MX2012013465A - Lactamas sustituidas con piperidinilo como moduladores de gpr119. - Google Patents
Lactamas sustituidas con piperidinilo como moduladores de gpr119.Info
- Publication number
- MX2012013465A MX2012013465A MX2012013465A MX2012013465A MX2012013465A MX 2012013465 A MX2012013465 A MX 2012013465A MX 2012013465 A MX2012013465 A MX 2012013465A MX 2012013465 A MX2012013465 A MX 2012013465A MX 2012013465 A MX2012013465 A MX 2012013465A
- Authority
- MX
- Mexico
- Prior art keywords
- piperidinyl
- substituted lactams
- gpr119 modulators
- gpr119
- modulators
- Prior art date
Links
- 150000003951 lactams Chemical class 0.000 title 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 abstract 1
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Compuestos de la Fórmula I: y sales farmacéuticamente de ellos, en donde X1, X2, L, R3, R4, R5, R6, R6a, R7, R9, R9a, y n tienen las definiciones que se dieron en la memoria descriptiva, son moduladores de GPR119 y son útiles en el tratamiento o la prevención de enfermedades tales como, en forma no taxativa, diabetes tipo 2, complicaciones diabéticas, síntomas de la diabetes, síndrome metabólico, obesidad, dislipidemia y condiciones relacionadas.(Ver Formula).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34546110P | 2010-05-17 | 2010-05-17 | |
PCT/US2011/036443 WO2011146335A1 (en) | 2010-05-17 | 2011-05-13 | Piperidinyl-substituted lactams as gpr119 modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012013465A true MX2012013465A (es) | 2013-12-02 |
Family
ID=44584599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012013465A MX2012013465A (es) | 2010-05-17 | 2011-05-13 | Lactamas sustituidas con piperidinilo como moduladores de gpr119. |
Country Status (20)
Country | Link |
---|---|
US (1) | US8754226B2 (es) |
EP (1) | EP2571864A1 (es) |
JP (1) | JP2013530947A (es) |
KR (1) | KR20130113948A (es) |
CN (1) | CN103080101A (es) |
AR (1) | AR081197A1 (es) |
AU (1) | AU2011256455A1 (es) |
BR (1) | BR112012029395A2 (es) |
CA (1) | CA2799779A1 (es) |
CL (1) | CL2012003211A1 (es) |
CO (1) | CO6670520A2 (es) |
CR (1) | CR20120642A (es) |
IL (1) | IL223092A0 (es) |
MX (1) | MX2012013465A (es) |
RU (1) | RU2012154308A (es) |
SG (1) | SG185615A1 (es) |
TW (1) | TW201141849A (es) |
UY (1) | UY33392A (es) |
WO (1) | WO2011146335A1 (es) |
ZA (1) | ZA201209605B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8754226B2 (en) | 2010-05-17 | 2014-06-17 | Array Biopharma Inc. | Piperidinyl-substituted lactams as GPR119 modulators |
EP2718279B1 (en) | 2011-06-09 | 2016-08-10 | Rhizen Pharmaceuticals SA | Novel compounds as modulators of gpr-119 |
KR101415742B1 (ko) * | 2011-12-21 | 2014-07-04 | 영남대학교 산학협력단 | 6―아미노피리딘―3―올 유도체 또는 이의 약제학적 허용가능한 염 및 이를 유효성분으로 함유하는 혈관신생으로 인한 질환의 예방 또는 치료용 약학조성물 |
EP2872127A1 (en) | 2012-07-11 | 2015-05-20 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
US9499482B2 (en) | 2012-09-05 | 2016-11-22 | Bristol-Myers Squibb Company | Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists |
AR092924A1 (es) | 2012-10-09 | 2015-05-06 | Sanofi Sa | Derivados de pirrolidinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
CN105431435A (zh) * | 2013-06-07 | 2016-03-23 | 拜耳制药股份公司 | 具有作为mps-1抑制剂的活性的取代的三唑并吡啶类 |
AR099936A1 (es) * | 2014-04-04 | 2016-08-31 | Sanofi Sa | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados |
AR099937A1 (es) | 2014-04-04 | 2016-08-31 | Sanofi Sa | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
RU2016143092A (ru) * | 2014-04-04 | 2018-05-08 | Санофи | Замещенные соединения инданона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений |
JP6649279B2 (ja) | 2015-01-19 | 2020-02-19 | 株式会社フジミインコーポレーテッド | 変性コロイダルシリカおよびその製造方法、並びにこれを用いた研磨剤 |
TWI763621B (zh) * | 2015-01-19 | 2022-05-11 | 日商福吉米股份有限公司 | 研磨用組成物之製造方法 |
EP3390399A1 (en) | 2015-12-17 | 2018-10-24 | Syngenta Participations AG | Microbiocidal oxadiazole derivatives |
EP3585775B1 (en) | 2017-02-21 | 2022-04-06 | Sanofi | Azetidine compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders |
EP4153589A1 (en) | 2020-05-19 | 2023-03-29 | Kallyope, Inc. | Ampk activators |
JP2023531020A (ja) | 2020-06-22 | 2023-07-20 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | スルホン誘導体 |
CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
CN114539073A (zh) * | 2022-02-18 | 2022-05-27 | 郑州萃智医药科技有限公司 | 3-溴-2-氯-4,6-二氟苯胺的合成方法 |
WO2024033374A1 (en) | 2022-08-11 | 2024-02-15 | Syngenta Crop Protection Ag | Novel arylcarboxamide or arylthioamide compounds |
WO2024089216A1 (en) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Novel sulfur-containing heteroaryl carboxamide compounds |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
WO2005061489A1 (en) | 2003-12-24 | 2005-07-07 | Prosidion Limited | Heterocyclic derivatives as gpcr receptor agonists |
EP1732885A1 (en) | 2004-02-23 | 2006-12-20 | Trustees Of Tufts College | Lactams as conformationally constrained peptidomimetic inhibitors |
TW200610761A (en) | 2004-04-23 | 2006-04-01 | Astrazeneca Ab | Chemical compounds |
CN1997640A (zh) | 2004-06-04 | 2007-07-11 | 艾尼纳制药公司 | 作为代谢调节剂的经取代芳基和杂芳基衍生物及其相关病症的预防和治疗 |
EP1817302A4 (en) * | 2004-11-22 | 2009-07-01 | Merck & Co Inc | PIPERIDINYLPIPERIDIN-tachykinin receptor Antagonist |
US7423043B2 (en) * | 2005-02-18 | 2008-09-09 | Lexicon Pharmaceuticals, Inc. | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds |
US20090264650A1 (en) * | 2005-03-31 | 2009-10-22 | Nobuo Cho | Prophylactic/Therapeutic Agent for Diabetes |
TW200724139A (en) | 2005-05-05 | 2007-07-01 | Warner Lambert Co | Androgen modulators |
US20090203676A1 (en) | 2005-06-30 | 2009-08-13 | Oscar Barba | G-protein Coupled Receptor Agonists |
US20100063081A1 (en) | 2005-06-30 | 2010-03-11 | Stuart Edward Bradly | CPCR Agonists |
US20080025795A1 (en) * | 2006-07-28 | 2008-01-31 | Cliff Purnell | Methods, apparatus and system for drain tiles |
US20080103123A1 (en) * | 2006-08-30 | 2008-05-01 | Biovitrum | New compounds |
JP2010513488A (ja) | 2006-12-20 | 2010-04-30 | メルク・シャープ・エンド・ドーム・コーポレイション | ビピペリジニル化合物、その化合物を含有する組成物及び治療方法 |
AU2008279447A1 (en) | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders |
US20110230507A1 (en) | 2008-07-10 | 2011-09-22 | Prosidion Limited | Piperidine GPCR Agonists |
TW201006821A (en) | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
CN107011330B (zh) * | 2009-09-04 | 2020-07-03 | 比奥根Ma公司 | 布鲁顿酪氨酸激酶抑制剂 |
CN102918027A (zh) | 2010-04-06 | 2013-02-06 | 艾尼纳制药公司 | Gpr119受体调节剂和对与所述受体有关的障碍的治疗 |
US8754226B2 (en) | 2010-05-17 | 2014-06-17 | Array Biopharma Inc. | Piperidinyl-substituted lactams as GPR119 modulators |
RU2013117403A (ru) | 2010-09-17 | 2014-10-27 | Эррэй Биофарма Инк. | Пиперидинил-замещенные лактамы как модуляторы gpr119 |
WO2013066869A1 (en) | 2011-11-03 | 2013-05-10 | Array Biopharma Inc. | Piperidinyl-substituted lactams as gpr119 modulators |
US20140309226A1 (en) | 2011-11-16 | 2014-10-16 | Array Biopharma Inc. | Piperidinyl-substituted cyclic ureas as gpr119 modulators |
-
2011
- 2011-05-13 US US13/698,257 patent/US8754226B2/en not_active Expired - Fee Related
- 2011-05-13 JP JP2013511238A patent/JP2013530947A/ja not_active Withdrawn
- 2011-05-13 WO PCT/US2011/036443 patent/WO2011146335A1/en active Application Filing
- 2011-05-13 CN CN2011800291586A patent/CN103080101A/zh active Pending
- 2011-05-13 AU AU2011256455A patent/AU2011256455A1/en not_active Abandoned
- 2011-05-13 KR KR1020127032867A patent/KR20130113948A/ko not_active Application Discontinuation
- 2011-05-13 EP EP11754769A patent/EP2571864A1/en not_active Withdrawn
- 2011-05-13 BR BR112012029395A patent/BR112012029395A2/pt not_active IP Right Cessation
- 2011-05-13 MX MX2012013465A patent/MX2012013465A/es not_active Application Discontinuation
- 2011-05-13 SG SG2012084471A patent/SG185615A1/en unknown
- 2011-05-13 CA CA2799779A patent/CA2799779A1/en not_active Abandoned
- 2011-05-13 RU RU2012154308/04A patent/RU2012154308A/ru not_active Application Discontinuation
- 2011-05-17 UY UY0001033392A patent/UY33392A/es not_active Application Discontinuation
- 2011-05-17 AR ARP110101683A patent/AR081197A1/es unknown
- 2011-05-17 TW TW100117276A patent/TW201141849A/zh unknown
-
2012
- 2012-11-16 CL CL2012003211A patent/CL2012003211A1/es unknown
- 2012-11-18 IL IL223092A patent/IL223092A0/en unknown
- 2012-12-17 CO CO12228271A patent/CO6670520A2/es not_active Application Discontinuation
- 2012-12-17 CR CR20120642A patent/CR20120642A/es unknown
- 2012-12-18 ZA ZA2012/09605A patent/ZA201209605B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2571864A1 (en) | 2013-03-27 |
RU2012154308A (ru) | 2014-06-27 |
US20130158009A1 (en) | 2013-06-20 |
WO2011146335A1 (en) | 2011-11-24 |
US8754226B2 (en) | 2014-06-17 |
CL2012003211A1 (es) | 2013-04-26 |
AU2011256455A1 (en) | 2013-01-10 |
TW201141849A (en) | 2011-12-01 |
CA2799779A1 (en) | 2011-11-24 |
ZA201209605B (en) | 2014-05-28 |
BR112012029395A2 (pt) | 2016-07-26 |
AR081197A1 (es) | 2012-07-04 |
IL223092A0 (en) | 2013-02-03 |
SG185615A1 (en) | 2012-12-28 |
KR20130113948A (ko) | 2013-10-16 |
UY33392A (es) | 2012-11-30 |
CO6670520A2 (es) | 2013-05-15 |
CN103080101A (zh) | 2013-05-01 |
CR20120642A (es) | 2013-03-11 |
JP2013530947A (ja) | 2013-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012013465A (es) | Lactamas sustituidas con piperidinilo como moduladores de gpr119. | |
MX2013003034A (es) | Lactamas piperidinilo-substituidas como moduladores de gpr119. | |
IN2012DN01233A (es) | ||
NZ705135A (en) | Heteroaryl compounds and methods of use thereof | |
IN2015DN01156A (es) | ||
MX2012000973A (es) | Compuestos para la reduccion de produccion de beta- amiloide. | |
MX2011011854A (es) | Dihidropirimidinonas para uso como inhibidores de la bace2. | |
GEP20146125B (en) | Aminopyrimidines as syk inhibitors | |
MX2012012952A (es) | Compuestos de 2, 5, 6, 7,-tetrahidro-[1, 4] oxazepin-3-ilamina o 2, 3, 6, 7-tetrahidro-[1, 4] oxazepin-5-ilamina. | |
MX344238B (es) | Compuestos de tetrazol y métodos para preparar y usar los mismos. | |
MX2011012017A (es) | Nuevos derivados azaciclicos como inhibidores de lipasa sensible a las hormonas (hsl). | |
IN2012DN03182A (es) | ||
WO2012096929A3 (en) | Heteroaryl compounds and methods of use thereof | |
MX2011010451A (es) | Derivados de oxadiazol. | |
PH12015500860A1 (en) | 2-phenyl -5- heterocyclyl -tetrahydro-2h- pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders | |
MX360554B (es) | Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2. | |
MX2013004759A (es) | Compuestos de oxima como agentes de elevacion de colesterol de lipoproteina de alta densidad (hdl). | |
IN2012DN00765A (es) | ||
MX349254B (es) | Compuestos para el tratamiento del sindrome metabolico. | |
MX2012000954A (es) | Composicion far,aceutica topica que incuye la rel-n-[6-[(2r,6s)-2,6-dimetil-4-morfolinil]-3-piridinil]-2-metil- 4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida. | |
EA201071183A1 (ru) | Безводная кристаллическая форма малеата орвепитанта | |
TN2011000531A1 (en) | 5- alkynyl - pyridines | |
MX2011011618A (es) | Agentes terapeuticos 713. | |
NZ702239A (en) | Heteroaryl compounds and methods of use thereof | |
MX2012001107A (es) | Derivado de amida. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |